scholarly journals Complete Response to Sorafenib Rechallenge in a Patient with Metastatic Renal Cell Carcinoma

2017 ◽  
Vol 2017 ◽  
pp. 1-3 ◽  
Author(s):  
Ryo Kasahara ◽  
Noboru Nakaigawa ◽  
Kazuki Kobayashi
Keyword(s):  
Cell Carcinoma ◽  
Clear Cell ◽  
Slow Growth ◽  
Renal Tumor ◽  
Clear Cell Carcinoma ◽  
Complete Response ◽  
Metastatic Lesion ◽  
Metastatic Lesions ◽  
Lumbar Vertebral Body ◽  
Old Japanese

A 79-year-old Japanese man underwent a medical examination for hoarseness. Computed tomography revealed a left renal tumor, and radical nephrectomy was performed. The tumor was a clear cell carcinoma. Fourteen months after the operation, the tumor had metastasized to the spleen, right lung, and retroperitoneal lymph nodes. We initiated molecular targeted therapy sequentially with sorafenib, sunitinib, and axitinib and then conducted a rechallenge with sorafenib. His metastatic lesions had completely vanished 5 months after initiation of the rechallenge. Ten months after the rechallenge, lumbar vertebral body metastasis appeared. However, we consider that the sorafenib rechallenge was effective because of the very slow growth of the metastatic lesion, with no other metastasis for 30 months, at the time of writing this report. Approximately 7 years after the first local recurrence, he remained alive, with relatively normal daily functioning.

Combination chemotherapy with temsirolimus and trabectedin in patients with heavily pretreated clear cell carcinoma of the ovary.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. e16519-e16519
Author(s):  
Masashi Takano ◽  
Hiroko Kouta ◽  
Naoki Sasaki ◽  
Kazuya Kudoh ◽  
Tsunekazu Kita ◽  
...  
Keyword(s):  
Adverse Effects ◽  
Combination Therapy ◽  
Cell Carcinoma ◽  
Clear Cell ◽  
Clear Cell Carcinoma ◽  
Mammalian Target Of Rapamycin ◽  
Response Duration ◽  
Complete Response ◽  
Marine Natural Product ◽  
Median Response

e16519 Background: Clear cell carcinoma (CCC) of the ovary showed exceedingly chemo-resistant phenotype, especially in the case with recurrent or refractory to previous therapy. An inhibitor against the mammalian target of rapamycin (mTOR), temsirolimus, has been reported to be effective in renal CCC. Additionally, a marine natural product, trabectedin, had activity against recurrent ovarian cancers. We evaluated the effect of combination therapy with temsirolimus and trabectedin for patients with recurrent/refractory CCC of the ovary. Methods: Patients with recurrent/refractory CCC of the ovary were treated with weekly regimen using two drugs: 10mg/m2 of temsirolimus and 0.15mg/m2 of trabectedin (3 weeks, one week rest) with written informed consents. Treatment was continued until development of progressive disease (PD) or unmanageable adverse effects. Responses were evaluated by RECIST criteria, and adverse effects were analyzed by NCI-CTCAE v4.0. Results: A total of 12 patients treated with the regimen, and there were no cases that discontinued the therapy due to toxicities. Median age was 60 years (range: 42-69), and median number of previous chemotherapy was 3 (range: 1-5). All cases were assessable by RECIST and CTCAE. One patient (8%) had a complete response (CR), and another (8%) achieved a partial response (PR), and 4 patients (33%) had stable disease (SD) beyond three months, resulting in clinical benefit rate (CBR; CR+PR+SD>3month) of 50%. Median response duration in CBR case was 3.5 months (range: 3-12+). There were no cases that developed toxicities more than grade2. Conclusions: The present preliminary study demonstrated combination therapy with temsirolimus and trabectedin was effective in patients with recurrent/refractory CCC of the ovary. These results warrant further study in such clinical settings.

scholarly journals Solitary metastatic clear cell carcinoma to the spleen

Rare Tumors ◽  
2011 ◽  
Vol 3 (4) ◽  
pp. 135-138
Author(s):  
Mohamed A. Zayed ◽  
Jon Kosek ◽  
Sherry M. Wren
Keyword(s):  
Lung Cancer ◽  
Cell Carcinoma ◽  
Clear Cell ◽  
Clear Cell Carcinoma ◽  
Latency Period ◽  
Metastatic Lesion ◽  
Abdominal Girth ◽  
Splenic Mass ◽  
Lung Lobectomy ◽  
Cystic Cavity

A 57-year-old with a 9-year history of increased abdominal girth, presented with increased abdominal pain, anemia, and acute renal failure. His past medical history was only remarkable for a previous lung cancer 21 years ago that was treated with a right upper lung lobectomy. A computed tomography (CT) scan of the patient's abdomen showed a solitary 20×20×25cm cystic splenic mass. The patient underwent an urgent splenectomy. Intra-operatively a large splenic cystic cavity was found with a solid inferior splenic mass. An exhaustive histological analysis of the splenic mass confirmed a clear cell carcinoma with low malignant potential that likely represented a metastatic lesion from the patient's previous distant lung cancer. Postoperatively the patient recovered well and at 1-year followup the patient demonstrated no further evidence of metastatic disease. This case is extremely unique and provides a very rare example of a metastatic solitary clear cell carcinoma to the spleen, with a presumed latency period of more than 20 years.

Pembrolizumab as adjuvant therapy in a patient with Lynch syndrome with synchronous mixed clear cell carcinoma of ovarian origin and endometroid endometrial carcinoma

2021 ◽  
Vol 14 (11) ◽  
pp. e245497
Author(s):  
Kathleen Batty ◽  
Minmin Li ◽  
Sally Baron-Hay
Keyword(s):  
Lynch Syndrome ◽  
Cell Carcinoma ◽  
Endometrial Carcinoma ◽  
Clear Cell ◽  
Clear Cell Carcinoma ◽  
Total Abdominal Hysterectomy ◽  
Complete Response ◽  
Abdominal Hysterectomy ◽  
High Index Of Suspicion ◽  
Percutaneous Thrombectomy

A 48-year-old woman was diagnosed with synchronous mixed clear cell carcinoma of ovarian origin and endometroid endometrial carcinoma after presenting with intermenstrual bleeding for 2 years prior. Shortly after diagnosis she became progressively unwell requiring intensive care unit admission with respiratory failure, pleural effusions and pulmonary emboli. Following a total abdominal hysterectomy, bilateral salpingo-oophorectomy, laparotomy and emergency percutaneous thrombectomy, she remained critically unwell and was deemed not safe for chemotherapy. Given a high index of suspicion for Lynch syndrome, the patient was treated with adjuvant pembrolizumab and achieved a complete response. Lynch syndrome was subsequently confirmed through germline genetic testing. The patient made an excellent recovery and remains disease-free at 23 months.

Phase II trial of motexafin gadolinium (MGd) for treatment of metastatic renal cell carcinoma (MRCC)

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 14518-14518
Author(s):  
A. Misellati ◽  
S. Phan ◽  
R. J. Amato
Keyword(s):  
Cell Carcinoma ◽  
Renal Cell ◽  
Clear Cell ◽  
Clear Cell Carcinoma ◽  
Collecting Duct ◽  
Performance Status ◽  
Hypoxia Inducible Factor ◽  
Thioredoxin Reductase ◽  
Complete Response ◽  
Motexafin Gadolinium

14518 Background: MGd inhibits thioredoxin reductase. Thioredoxin is implicated in activation of hypoxia-inducible factor-1 alpha, which is overexpressed in >85% of renal cell carcinomas (RCC). We evaluated anti-tumor and safety activity of MGd in patients (pts) with progressive MRCC. Methods: Eligibility included: measurable MRCC, adequate organ/marrow function, zubrod performance status (ZPS) ≤2, life expectancy ≥12 weeks, ≤2 prior therapies and no active CNS involvement. MGd was infused intravenously over 30 minutes at 5mg/kg on days 1–5 and 15–19 of each 28-day cycle. Evaluation was performed after every 3 cycles. RECIST criteria were utilized to determine response rate. Time to progression (TTP) is determined from time of study entry. Results: 25 evaluable pts were enrolled 19 male/6 female, median age 63 years (range 38–76). All pts had histologic confirmed RCC; 9 pts had clear cell carcinoma, 9 pts with predominant clear cell carcinoma component, 2 pts with papillary and 1 pt with collecting duct. 23 pts received prior systemic therapy, median 2 treatments. 16 pts had ZPS of 0, 8 pts had ZPS of 1, and 1 pt had ZPS of 2. All pts had progressive MRCC. Sites of disease included: lung, nodal, bone, adrenal, kidney and liver. 7 pts had 1 metastatic site, 6 pts had 2 and 12 pts had 3 or more. 20 pts have completed at least 12 weeks of therapy. 5 pts progressed within 3 months. 1 pt had a complete response of lung metastasis but progressed in the CNS. Median TTP is 12 weeks (3–69). Median overall survival is 10.1+ months (1–19+). Grade 1/2 toxicity consisted of: skin discoloration, fatigue, nausea, and headache. Grade 3/4 toxicity consisted of: blisters of the digits and hypophosphatemia. Conclusions: MGd was well tolerated and stabilization of disease was observed in pts with progressive disease. These results show promise for MGd in the previously treated MRCC population and potentially can be used in combination with other MRCC agents. [Table: see text]

A Case of Renal Clear Cell Carcinoma Presenting with a Metastatic Lesion in the Oropharynx

2018 ◽  
Vol 111 (4) ◽  
pp. 271-276
Author(s):  
Masayuki Kitano ◽  
Ryusuke Hori ◽  
Tsuyoshi Kojima ◽  
Yusuke Okanoue ◽  
Shintaro Fujimura ◽  
...  
Keyword(s):  
Cell Carcinoma ◽  
Clear Cell ◽  
Clear Cell Carcinoma ◽  
Metastatic Lesion ◽  
Renal Clear Cell Carcinoma

A Thyroid Metastasis Revealing an Occult Renal Clear-Cell Carcinoma

1987 ◽  
Vol 73 (2) ◽  
pp. 187-190 ◽  
Author(s):  
Silvio Dal Fabbro ◽  
Gaetano Monari ◽  
Renzo Barbazza
Keyword(s):  
Cell Carcinoma ◽  
Clear Cell ◽  
Clear Cell Carcinoma ◽  
Needle Aspiration ◽  
Metastatic Lesion ◽  
Renal Clear Cell Carcinoma ◽  
Thyroid Metastasis ◽  
Thyroid Lesion ◽  
Pas Staining ◽  
Needle Aspiration Cytology

A case of renal clear-cell carcinoma presenting as a nodular thyroid metastasis is reported. The possibility of a metastatic lesion from the kidney should be taken into account in each case of clear-cell thyroid lesion. Fine needle aspiration cytology may be unable to discriminate between the renal or thyroid origin of such lesions unless PAS staining is performed.

Metastatic renal tumor presenting as ovarian clear cell carcinoma

Urology ◽  
1993 ◽  
Vol 41 (6) ◽  
pp. 582-584 ◽  
Author(s):  
Julia R. Spencer ◽  
Brenda Eriksen ◽  
John E. Garnett
Keyword(s):  
Cell Carcinoma ◽  
Clear Cell ◽  
Renal Tumor ◽  
Clear Cell Carcinoma ◽  
Ovarian Clear Cell Carcinoma
Sign in / Sign up

Export Citation Format

Share Document